Investor Relations

MiNK Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel, first-in-class invariant natural killer T (iNKT) cell therapies to transform the lives of patients with cancer.
Press Releases
Nov 09, 2023
MiNK Therapeutics Reports Third Quarter 2023 Results
MiNK presents first-of-a-kind data with allogeneic iNKTs, agenT-797, showing durable clinical benefit in solid tumor cancers and persistence >6 months without toxic pre-conditioning. AgenT-797 demonstrates potential beyond cancer, with improved survival in severe respiratory distress.
Oct 30, 2023
MiNK to Provide Third Quarter 2023 Financial Report and Corporate Update
NEW YORK , Oct. 30, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics , Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other
Corporate Presentation

SEC Filings

Form Description Filing date View
10-K

Annual report which provides a comprehensive overview of the company for the past year

 View HTML
0001564590-22-011026.pdf
0001564590-22-011026.rtf
0001564590-22-011026.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
10-K

Annual report which provides a comprehensive overview of the company for the past year

 View HTML
0000950170-23-009762.pdf
0000950170-23-009762.rtf
0000950170-23-009762.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
10-Q

Quarterly report which provides a continuing view of a company's financial position

 View HTML
0001564590-21-058700.pdf
0001564590-21-058700.rtf
0001564590-21-058700.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
10-Q

Quarterly report which provides a continuing view of a company's financial position

 View HTML
0001564590-22-020146.pdf
0001564590-22-020146.rtf
0001564590-22-020146.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA

Data provided by Kaleidoscope.

Events and Presentations